The Program — What Happens Next — The Evidence — About Dr. Hare — Why Physician-Led The Limitless Protocol Why Limitless Services — Hormone Therapy — Low Testosterone — Testosterone Pellets — Women's Hormone Therapy — Medical Weight Loss — Tirzepatide — Semaglutide — Moving Your GLP-1 Care — Peptide Therapy — Peptide Menu — Cognitive Peptides — IV Therapy & NAD+ — NAD+ IV near Chattanooga — Cost & Payment Research — Retatrutide Update — Peptide Reclassification Update — The Case for Creatine Locations Assessment Request a consultation
Research · Regulatory · Status read · June 2026

Peptide reclassification, plainly.

Where compounded peptides actually stand as of June 2026 — seven peptides, one docket, and the single distinction the headlines keep blurring. Dated on purpose, because this is a moving target.
Joshua Hare, DO · 6 min read · Published 2026-06-11
PCAC meeting concluded — read the post-vote analysis

Update, October 8, 2026: the meeting took place on July 23–24, and the committee recommended six of the seven peptides it reviewed. The recommendation is advisory; our post-vote analysis, which supersedes this status read, covers what it changes and what it does not yet change.

Update, November 5, 2026: on October 30, HHS published an interim enforcement policy covering six peptides: BPC-157, KPV, TB-500, MOTS-c, Semax and Epitalon. DSIP is not covered. HHS says it does not intend to take enforcement action against compounding that meets the policy's conditions until a final rule addresses each peptide. The policy is not binding, the Federal Register notice calls it a draft and sets a two-week comment period, and none of the six has been added to the 503A bulks list. The rest of this article is kept as it was published in June.

If you have searched "are peptides legal in 2026" recently, you have probably found two kinds of pages: breathless ones claiming peptides are "back," and alarmed ones claiming they are "banned." Both are wrong, and the truth is more boring and more useful. Here is the dated, plain-language status as of June 21, 2026 — 32 days before the vote.

The one distinction that explains everything.

Three different things keep getting collapsed into one in the coverage. Keep them separate and the whole picture clears up:

"A recommendation is not a rule. Even a unanimous 'include' vote in July sends a peptide into FDA rulemaking that typically runs more than a year before anything about lawful compounding changes."

What is on the docket.

The July meeting sits under FDA docket FDA-2025-N-6895. Seven peptides are scheduled across two days. Notably, the day-one peptides were each posted as two nominations — a free-base form and an acetate salt form — which the committee can evaluate separately.

PeptideCategory
Day 1 — Thursday, July 23, 2026
BPC-157 (free base / acetate)Tissue-repair & recovery
TB-500 (free base / acetate)Tissue-repair & recovery
MOTS-c (free base / acetate)Mitochondrial / metabolic
KPV (free base / acetate)Anti-inflammatory
Day 2 — Friday, July 24, 2026
Emideltide (DSIP)Sleep — not a Limitless protocol
SemaxCognitive — not a default protocol
EpitalonLongevity claim — research-watch only

What is not on the docket.

Two points worth stating plainly, because they are the most common source of confusion:

This is the first of two reviews.

The July 23–24 meeting is not the FDA's final word. The agency has signaled a second PCAC meeting before the end of February 2027 to evaluate an additional five peptide substances; that slate has not yet been published. The practical takeaway: peptide regulation across 2026–2027 is a rolling process, not a one-day verdict. A peptide absent from the July docket is not "banned" — it may simply be queued for the next round.

What a patient should actually do with this.

  1. Don't act on headlines. "Peptides are back" and "peptides are banned" are both inaccurate. The operative legal status today is unchanged by a vote that hasn't happened.
  2. Ask where your peptide is sourced. The honest answer from any clinic should be a licensed 503A compounding pharmacy — never a research-chemical vendor. If a clinic can't tell you, that is the real red flag, not the PCAC calendar.
  3. Expect a slow clock after July. Even a favorable vote starts a rulemaking process measured in quarters-to-years, not days. Nobody's compounded prescription appears on a new legal footing in August because of a July vote.
  4. Watch the dated updates. We will post the actual committee outcomes within seven days of the vote, and a plain read of the early-2027 slate when the FDA publishes it.

The bottom line.

As of June 2026: seven peptides are scheduled for an advisory review on July 23–24 under docket FDA-2025-N-6895; that review produces a recommendation, not a law; the law changes only later, through rulemaking, if at all; FDA-approved molecules at the core of the Limitless protocol library are untouched by any of it; and a second review is already coming in early 2027. That is the whole picture, and it is a calmer picture than either side of the internet is selling.

If you just want the patient version — what this means for your care in three minutes — read the patient FAQ. For the deeper docket analysis with vote-by-vote scenarios, see what to expect at the July PCAC and the live PCAC Watch tracker.

Primary sources

  1. FDA — Pharmacy Compounding Advisory Committee Meeting, July 23–24, 2026 (docket FDA-2025-N-6895). fda.gov
  2. FDA — Certain Bulk Drug Substances for Use in Compounding (503A bulks landing page). fda.gov
  3. Regulations.gov — public comment portal for docket FDA-2025-N-6895 (window open through July 22, 2026). regulations.gov
  4. Companion Limitless research: what to expect at the July PCAC, PCAC Watch tracker, 503A / 503B / RUO sourcing explained, peptides legal status 2026.
Authored by Joshua Hare, DO — founder, Limitless Performance Medicine. Dated June 21, 2026 (reviewed against the FDA docket); the post-vote update was added on October 8, 2026 and the HHS update on November 5, 2026.
← Back to research
Now open · Dalton, GA · By appointment

Physician-led care in Dalton, Georgia.

Limitless Performance Medicine is a physician-led practice. Consultations are by appointment.

Dr. Hare also founded Interventional Pain Consultants (IPC), which shares our building in Dalton. This number is IPC's main Dalton line.

Take the Assessment · 90 sec